Abstract: The present disclosure describes a method for targeted delivery of permanently-acting or temporarily-acting neurotoxins, neurosuppressants, or other compounds having a neurologic effect to specific locations of the heart, including for example, but not limited to, nodes of the cardiac autonomic nervous system such as the atrial ganglionated plexi (GP). Chemical ablation of the atrial GP as described herein via magnetically-targeted magnetically-susceptible nanoparticles can effectively suppress GP activity and atrial fibrillation related, thereto without permanent damage to either myocardium or intrinsic CANS.

Abstract: Disclosed are methods of treatment or prophylaxis of a disease state or a condition ameliorated or prevented by electromagnetic field application. A person having or susceptible to such disease state or condition is subjected to electromagnetic fields having a frequency between zero and about 200 Hertz. The diseased state or condition may include diseased heart valves, an enlarged heart, circulatory blockage, coronary insufficiencies, and ischemia. The treatment may be administered non-invasively or invasively. An implantable device for invasively administering the treatment may include at least one component emitting electromagnetic fields having a frequency between zero and about 200 Hertz. The component may include at least one inductor.

Abstract: The present disclosure describes a method for targeted delivery of permanently-acting or temporarily-acting neurotoxins, neurosuppressants, or other compounds having a neurologic effect to specific locations of the heart, including for example, but not limited to, nodes of the cardiac autonomic nervous system such as the atrial ganglionated plexi (GP). Chemical ablation of the atrial GP as described herein via magnetically-targeted magnetically-susceptible nanoparticles can effectively suppress GP activity and atrial fibrillation related, thereto without permanent damage to either myocardium or intrinsic CANS.

Abstract: Disclosed are methods of treatment or prophylaxis of a cardiac-related condition by electromagnetic field application. A person having or susceptible to such condition is subjected to low-level electromagnetic fields having a frequency between zero up to about 200 Hertz. The diseased state or condition may include diseased heart valves, an enlarged heart, circulatory blockage, coronary insufficiencies, and ischemia. The treatment may be administered non-invasively or invasively. An implantable device for invasively administering the treatment may include at least one component emitting electromagnetic fields having a frequency between zero and about 200 Hertz. The component may include at least one inductor.

Abstract: A method of treatment or prophylaxis of a disease state or a condition ameliorated or prevented by electromagnetic field application. A person having or susceptible to such disease state or condition is subjected to electromagnetic fields having a frequency between zero and about 200 Hertz. The diseased state or condition may include diseased heart valves, an enlarged heart, circulatory blockage, coronary insufficiencies, and ischemia. The treatment may be administered non-invasively or invasively. An implantable device for invasively administering the treatment may include at least one component emitting electromagnetic fields having a frequency between zero and about 200 Hertz. The component may include at least one inductor.

Abstract: The present invention provides a method of controlling cardiac fibrillation, tachycardia, or cardiac arrhythmia by the use of an electrophysiology catheter having a tip section that contains at least one stimulating electrode, the electrode being stably placed at a selected intravascular location. The electrode is connected to a stimulating means, and stimulation is applied across the wall of the vessel, transvascularly, to a sympathetic or parasympathetic nerve that innervates the heart at a strength sufficient to depolarize the nerve and effect the control of the heart.

Abstract: 3,7-Diazabicyclo[3.3.1]nonanes and selected derivatives thereof of the general formula: ##STR1## are disclosed as multiclass antiarrhythmic agents.

Abstract: A method for alleviating and diagnosing syndromes of heart block wherein a stimulus is continuously or intermittently delivered via a single electrode catheter at a site in a heart in close proximity to the A-V junction in the heart. The subthreshold stimuli were sufficient to cause impulses in the atrium to pass through the damaged His bundle to the ventricle and the stimuli were set at a level below a level required to excite the heart tissue. The delivery of the stimuli alleviates the symptoms of heart block. In one application, the delivery of the stimuli is used for diagnosing heart block when delivery of the stimuli induces the symptoms of heart block in the patient with partial or covert conduction disease.

Abstract: 3-7-Diheterabicyclo[3.3.1]nonanes and derivatives thereof are disclosed. Their method of preparation and use as antiarrhythmic agents is given.

Abstract: Salts of 3-azabicyclo[3.3.1]nonanes are used in controlling antiarrhythmic processes and precursors thereof are disclosed.

Abstract: Salts of 3-azabicyclo[3.3.1]nonanes are used in controlling antiarrhythmic processes and precursors thereof are disclosed.

Abstract: A method for alleviating and diagnosing syndromes of heart block wherein a stimulus is continuously or intermittently delivered via a single electrode catheter at a site in a heart in close proximity to the A-V junction in the heart. The subthreshold stimuli were sufficient to cause impulses in the atrium to pass through the damaged His bundle to the ventricle and the stimuli were set at a level below a level required to excite the heart tissue. The delivery of the stimuli alleviates the symptoms of heart block. In one application, the delivery of the stimuli is used for diagnosing heart block when delivery of the stimuli induces the symptoms of heart block in the patient with partial or covert conduction disease.

Abstract: 3-7-Diheterabicylo[3.3.1]nonanes and derivatives thereof are disclosed. Their method of preparation and use as antiarrhythmic agents is given.

Abstract: 3-7-Diheterabicyclo[3.3.1]nonanes and derivatives thereof are disclosed. Their method of preparation and use as antiarrhythmic agents is given.

Abstract: 3-7,Diheterabicylo[3.3.1]nonanes and derivatives thereof are disclosed. Their method of preparation and use as antiarrhythmic agents is given.

Abstract: 3-7-Diheterabicylo[3.3.1]nonanes and derivatives thereof are disclosed. Their method of preparation and use as antiarrhythmic agents is given.

Abstract: 3-Thia-7-azabicyclo(3.3.1)nonanes and derivatives thereof are disclosed. The preparation of these compounds is given. Their use as antiarrhythmic agents is given.